1-2 of 2
Peter Hauff
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect

Free
Sven Golfier, Charlotte Kopitz, Antje Kahnert, Iring Heisler, Christoph A. Schatz, Beatrix Stelte-Ludwig, Anke Mayer-Bartschmid, Kerstin Unterschemmann, Sandra Bruder, Lars Linden, Axel Harrenga, Peter Hauff, Frank-Detlef Scholle, Beate Müller-Tiemann, Bertolt Kreft, Karl Ziegelbauer
Journal: Molecular Cancer Therapeutics
Series: Author Choice
Mol Cancer Ther (2014) 13 (6): 1537–1548.
https://doi.org/10.1158/1535-7163.MCT-13-0926
Published: 04 June 2014
View articletitled, Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect
Open the PDF for Anetumab Ravtansine: A Novel Mesothelin-Targeting Antibody–Drug Conjugate Cures Tumors with Heterogeneous Target Expression Favored by Bystander Effect in another window
Includes: Supplementary data
Journal Articles

Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects

Free
Moritz Palmowski, Jochen Huppert, Gesa Ladewig, Peter Hauff, Michael Reinhardt, Margareta M. Mueller, Eva C. Woenne, Juergen W. Jenne, Mathias Maurer, Guenter W. Kauffmann, Wolfhard Semmler, Fabian Kiessling
Journal: Molecular Cancer Therapeutics
Mol Cancer Ther (2008) 7 (1): 101–109.
https://doi.org/10.1158/1535-7163.MCT-07-0409
Published: 17 January 2008
View articletitled, Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects
Open the PDF for Molecular profiling of angiogenesis with targeted ultrasound imaging: early assessment of antiangiogenic therapy effects in another window